Table 5.
Summary statistics of inebilizumab clearance (mL/day) by antidrug antibody status
| Summary statistics | ADA status | ||
|---|---|---|---|
| ADA POS | ADA NEG | ADA combined | |
| Sample size | 158 | 16 | 174 |
| Mean ± SD | 195 ± 58.9 | 235 ± 58.5 | 199 ± 59.8 |
| Geometric mean | 187 | 228 | 191 |
| Median | 185 | 211 | 190 |
| Minimum; maximum | 91; 425 | 166; 359 | 91; 425 |
All summary statistics are rounded to three significant figures
ADA antidrug antibodies, ADA NEG ADA-negative subject with titer <50, ADA POS ADA-positive subject with titer ≥50, SD standard deviation